STAT+: A look at the next generation in biotech venture capital
The latest biotech updates, brought to you by The Readout newsletter.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Oh hi. Today, we talk about Eli Lilly’s plan to invest $27 billion into new manufacturing sites stateside, learn about a new wave of biotech VCs, and more.
The need-to-know this morning
- STAT’s Adam Feuerstein, in his weekly Biotech Scorecard newsletter, writes about a counterintuitive, but ingenious, solution to the “zombie” problem among biotechs: Buy them and shut them down.
- Argenx, Europe’s other top biotech, reported fourth-quarter and 2024 earnings.
Biotech’s new generation of venture capitalists
A new wave of biotech venture capital firms, led by younger investors, is reshaping the industry with fresh strategies and a focus on artificial intelligence, longevity, and computational biology. While traditional VC firms stay dominant, these newcomers — many in their 30s and 40s — are securing major funding and backing scientific founders.
